profit from every $100 of sales.
$0$100
Ventyx Biosciences
We have no price for Ventyx Biosciences since 6 March 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$14.00+0.00% today
+265.5% since Oct 8, 25
1-year low $3.561-year high $14.03
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Ventyx Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ventyx Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Ventyx Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 5.2×
- –
- –
- –
- -13.1%
- -13.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -58.0%
- -6.1%
- -48.1%
- -50.4%
- -58.3%
- –
Growth
- –
- –
- +21.5%
- –
- +8.0%
Financial health
- 0.2×
- 0.05
- 4.7%
- –
- 17.86
- 17.86
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 958
Bottom 21%of 888
Bottom 7%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Nov 6, 2025 | -0.32 | -0.45 | +28.9% |
| Aug 7, 2025 | -0.38 | -0.45 | +15.6% |
| May 8, 2025 | -0.39 | -0.48 | +18.7% |
| Feb 27, 2025 | -0.41 | -0.54 | +24.1% |
| Nov 7, 2024 | -0.50 | -0.48 | −4.2% |
| Aug 8, 2024 | -0.45 | -0.57 | +21.1% |
| May 9, 2024 | -0.62 | -0.67 | +7.5% |
| Feb 27, 2024 | -0.79 | -0.78 | −1.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
40No pass
Philip Fisher
34No pass
Peter Lynch
59No pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
30No pass
Questions about Ventyx Biosciences
Is Ventyx Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ventyx Biosciences AI analysis
What does Ventyx Biosciences do?
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. It is in Biotechnology.
Does Ventyx Biosciences pay a dividend?
No. Ventyx Biosciences does not pay a dividend at the moment.
Is Ventyx Biosciences stock halal?
Yes. Ventyx Biosciences passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
Who are Ventyx Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Ventyx Biosciences's.
Prices: daily closes to Mar 6, 2026. Fundamentals: company reports via invest-like data.